Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Melding Deep Industry Experience with Commercial Insight

Companies operating in the healthcare and life sciences sectors face an increasingly complex transactional, political, and competitive landscape. Latham’s superior grasp of the regulatory regimes and market issues means that clients can adroitly and expeditiously address litigation, mergers and acquisitions, capital raising, regulatory counseling, business restructuring and reorganization, contract negotiations, fraud and abuse compliance, white collar and government investigations, operational matters, and more.


For more information on Latham’s Healthcare experience and expertise visit the Healthcare Services & Providers Industry Group page

Life Sciences

For more information on Latham’s Life Sciences experience and expertise visit the Life Sciences Industry Group page

Awards & Rankings

  • Latham Again Named Washington, D.C. Intellectual Property Litigation Department of the Year - May 27, 2020
  • Healthcare & Life Sciences Partner Recognized as Top Healthcare Lawyer - May 05, 2020
  • San Diego Partner Named Healthcare Trailblazer - April 12, 2020
  • Two Latham Trial Victories Honored Among California’s Top Verdicts - February 26, 2020
  • Latham Named 2019 Life Sciences Group of the Year - February 12, 2020

Latham has a "strong bench of former government attorneys who field expertise across numerous US departments and offices" and a "dominant presence in qui tam suits and criminal proceedings, as well as frequent involvement in complex transactions, including high-value M&A.”

– Chambers USA 2020


Webcast – FDA Regulatory Updates and 2020 Outlook for Vaping and Cannabis-Derived SubstancesSecurities Enforcement Forum 2019 Webcast: Recent Developments in Health Care Enforcement

Media Coverage

Federal Circuit, Judge Nix CardioNet Heart Monitor Patent ClaimsLatham Strikes Again on Branded Pharma by Adding 2 LitigatorsDC Circ. Rejects Trump's 'Far-Flung' Drug Pricing Rule


Latham & Watkins Advises Pi-Cardia in Partnership with Venus Medtech to Bring Leaflex(TM) Aortic Valve Technology to ChinaLatham Advises Revolution Medicines in its $156 Million Public OfferingFirm Advises Juno Therapeutics in JW Therapeutics’ Series B Financing

Thought Leadership

COVID-19: Managing Worker Health & Safety Rise in Securities Class Action Filings in Life Sciences SectorCOVID-19: DHSC and MHRA Pave the Way for Increased Ventilator Production

Webcasts & Podcasts

FDA Regulatory Updates and 2020 Outlook for Vaping and Cannabis-Derived Substances